Eledon Pharmaceuticals to Present Updated Clinical Data for Tegoprubart at World Transplant Congress

Eledon Pharmaceuticals Inc. (NASDAQ:ELDN) is one of the stocks under $10 to buy now. On July 17, Eledon Pharmaceuticals announced that updated clinical data from its ongoing open-label Phase 1b study of tegoprubart will be presented at the World Transplant Congress/WTC. The WTC will take place in San Francisco from August 2-6 this year.

The oral presentation, titled “Tegoprubart, an Anti-CD40L Antibody, for the Prevention of Rejection in Kidney Transplantation: An Ongoing Phase 1b Study,” will feature updated results from ~30 kidney transplant recipients. In addition to the oral presentation, Eledon Pharmaceuticals will sponsor a satellite symposium at the WTC titled: “What Truly Defines Kidney Transplant Success: Early Rejection or Lasting Function?”

Furthermore, new preclinical data on tegoprubart’s use for preventing rejection in non-human primates undergoing liver transplantation will be presented in a poster session.

Eledon Pharmaceuticals Inc. (NASDAQ:ELDN) is a clinical-stage biotechnology company that uses its immunology expertise in targeting the CD40 Ligand/CD40L pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis/ALS.

While we acknowledge the potential of ELDN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.